AML is currently the most common indication for reduced-intensity conditioned (RIC) allo-SCT. Reduced-intensity regimens allow a potent GVL response to occur with minimized treatment-related toxicity in patients of older age or with comorbidities that preclude the use of myeloablative conditioning. Whether RIC SCT is appropriate for younger and more standard risk patients is not well defined and the field is changing rapidly; a prospective randomized trial of myeloablative vs RIC (BMT-CTN 0901) was recently closed when early results indicated better outcomes for myeloablative regimens. However, detailed results are not available, and all patients in that study were eligible for myeloablative conditioning. RIC transplants will likely remain the standard of care as many patients with AML are not eligible for myeloablative conditioning. Recent publication of mature results from retrospective and prospective cohorts provide contemporary efficacy and toxicity data for these attenuated regimens. In addition, recent studies explore the use of alternative donors, introduce regimens that attempt to reduce toxicity without reducing intensity, and identify predictive factors that pave the way to personalized approaches. These studies paint a picture of the future of RIC transplants. Here we review the current status of RIC allogeneic SCT in AML. ( 
EFFICACY-IS THERE AN IDEAL CONDITIONING REGIMEN?
The definition of RIC has been a moving target. The term 'reduced intensity' describes regimens characterized by lower rates of toxicities compared with myeloablative transplants. RIC regimens can be further classified as non-myeloablative when they result in minimal cytopenias. These regimens presumably have minimal or no direct effect on leukemic cells, relying solely on the GVL response. 13 The CIBMTR defines a RIC regimen as single-dose TBI ⩽ 5 Gy or fractionated TBI ⩽ 8 Gy, BU doses ⩽ 9 mg/kg or melphalan doses ⩽ 150 mg/m 2 .
14 Table 1 lists commonly used RIC regimens according to the CIBMTR. Most regimens are conceptually similar in their goal to reduce regimen-related toxicity while allowing engraftment, but differ in the specific composition and dosing of cytotoxic and immunosuppressive agents, as well as the addition of T-cell depleting agents. The most frequently used regimens combine fludarabine with either low-dose TBI (Flu/TBI2) or an alkylating agent (BU, CY or melphalan).
The ideal conditioning regimen for RIC SCT is not known. A prospective comparison of these regimens has never been conducted though data suggest that the choice of alkylating agent is less important than its dose. [15] [16] [17] [18] [19] [20] [21] [22] Recent studies that included primarily AML patients are summarized in Table 2 . Most of these are single-arm studies, and differences may be driven by patient selection rather than regimen. The inclusion of multiple diseases in some studies limits interpretation since other diseases such as MDS and myeloproliferative neoplasms may have different outcomes and prognostic factors compared with AML. Despite their limitations, a limited number of comparative studies suggest that regimen intensity is directly associated with non-relapse mortality (NRM) and inversely associated with relapse, leading to equivalent survival rates regardless of regimen intensity.
respectively. The outcome for patients transplanted for refractory leukemia was poor with 18% surviving 5 years. Interestingly, older age did not predict a higher relapse risk after adjustment for other variables.
Another well-studied regimen is fludarabine combined with a non-myeloablative dose of BU. Using either 3.2 or 6.4 mg/kg of i.v. BU, this regimen resulted in similar 2-year PFS and OS rates of 40 and 48%, respectively, although the groups in this retrospective study were not balanced. 28 At these doses, i.v. BU has a favorable toxicity profile and does not require pharmacokinetic monitoring. These advantages contribute to the wide use of this regimen (Table 1) . A combination of fludarabine and melphalan (Flu/Mel) is also commonly used and results from MD Anderson demonstrated 2-year OS of 44% in 112 patients with AML or MDS, but significantly better OS of 66% in a subset of patients who were in CR at the time of transplant. 29 A retrospective comparison between Flu/Bu and Flu/Mel regimens demonstrated lower relapse risk but possibly higher NRM for Flu/Mel, resulting in similar survival. 24 RIC regimens will likely evolve over time; experimental regimens incorporate potent antileukemic agents (for example, clofarabine, a second-generation purine analog) or radiolabeled antibodies (for example, 131 I-labeled-anti-CD45 Ab) to account for the suboptimal antileukemic activity of RIC regimens. Promising results have been reported even in high-risk patients. [30] [31] [32] [33] [34] [35] Reduced intensity or reduced toxicity? Several conditioning regimens are considered myeloablative but characterized by reduced toxicity. Treosulfan, a novel alkylating agent, has shown promise in single-arm clinical trials of younger patients. 36, 37 Another myeloablative regimen with reduced toxicity uses a combination of fludarabine and high-dose BU (Flu/Bu4). [38] [39] [40] The Flu/Bu4 regimen has been compared with BU/CY in patients with leukemia or MDS, showing increased relapse and no benefit in terms of NRM for Flu/Bu4. 41 A similar study in AML patients in first remission showed similar rates of relapse and survival but less regimen-related toxicity for Flu/Bu4. 42 Neither study used targeted BU dosing and both enrolled primarily young patients. Randomized studies comparing reduced toxicity to reduced-intensity regimens in older patients are lacking, but a recent retrospective comparison of two Flu/Bu/ ATG regimens with different BU doses failed to show statistically significant survival differences, although outcomes using higher BU were numerically better. 43 In summary, it is difficult to establish if these newer regimens have significant advantages over traditional RIC regimens.
Another approach that attempts to improve disease control uses a standard RIC regimen administered at the time of aplasia from leukemia induction. Several studies described favorable outcomes for high-risk patients (that is, complex karyotype, secondary AML or primary refractory AML) who received fludarabine, ara-C and amsacrine followed by a standard RIC regimen. Two-year survival rates in patients with primary refractory AML ranged between 39 and 69% in studies using this regimen, and a subset of elderly patients (age ⩾ 60) had lower survival of 31%. [44] [45] [46] [47] Comparative studies between this approach and alternative regimens are still lacking.
T-cell depleting antibodies T-cell depletion aims to decrease GvHD though may compromise the critical GVL effect. The most commonly used T-cell depletion antibodies have been anti-thymocyte globulin (ATG) that depletes T cells in vivo and has additional immunomodulatory effects, and alemtuzumab (monoclonal anti-CD52 Ab) that depletes T cells, B cells and DCs.
A CIBMTR analysis showed that alemtuzumab halved the rates of acute and chronic GvHD and ATG significantly decreased chronic GvHD, but both increased relapse rates, leading to worse survival for ATG and no survival differences for alemtuzumab. 48 Similar European Group for Blood and Marrow Transplantation (EBMT) analyses confirmed the efficacy of in vivo T-cell depletion in preventing GvHD but without improvement in survival. 49, 50 The retrospective nature of these analyses makes them susceptible to selection bias, but since RIC SCT relies heavily on GVL activity, these outcomes are not surprising.
One of the challenges in analyzing the effect of in vivo T-cell depletion is that different studies use different drug formulations, dose ranges and schedules, often leading to conflicting results. [51] [52] [53] Another limitation is short follow-up, which limits the ability to assess the consequences of chronic GvHD, which is a major contributor to impaired long-term quality of life, 54, 55 and may justify the use of T-cell depleting strategies in the absence of a survival benefit. In particular, the equivalent survival seen when alemtuzumab was added to RIC regimens may support the use of this agent to improve quality of life secondary to lower rates of chronic GvHD.
A unique approach developed at Stanford University combines TLI with ATG. This regimen causes profound lymphopenia without significant myelosuppression, and creates a survival advantage for invariant natural killer T cells, which have a role in GvHD control. 56 A study that included 42 patients with AML showed low rates of acute GvHD and NRM, but the 3-year survival rate in patients with myeloid malignancies was 47%, due to a 450% relapse rate. 57 It is possible that judicious use of T-cell depletion in select patients at high risk of GvHD (for example, HLA-mismatched transplants) or low risk for relapse may improve outcome, but currently there is insufficient evidence to question standard use of T-cell depletion. This topic has been further reviewed elsewhere. 58 
GRAFT AND DONOR SOURCES
In choosing the graft source, mobilized PBSCs have usually been preferred to BM due to faster engraftment, 59 which may be important in more vulnerable, older patients. Furthermore, since RIC SCT relies on a strong GVL response, the 10-fold lower dose of T cells in BM grafts may be less desirable, especially in high-risk patients. 60 Prospective studies randomizing patients to BM vs PBSC in RIC SCT are lacking, but retrospective analyses demonstrated no significant differences in 2-year leukemia-free survival in AML patients transplanted in CR. 61, 62 Selection bias, small sample size for the BM group and relatively short follow-up remain the main limitations of these analyses. relapse.
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Survival after HLA-matched sibling or unrelated donor SCT seems to be similar, 16, 26, 63, 64 although HLA-mismatched donors (at one to two loci) result in inferior outcomes. 65, 66 Alternative sources such as umbilical cord blood (UCB) and haploidentical donors seem to be effective in RIC SCT. RIC transplants with a single UCB graft demonstrated engraftment rates similar to myeloablative transplants, and the 1-year survival rate in selected patients was~40% though with TRM as high as 38%, leaving room for improvement in safety and long-term survival. 67, 68 Attempts to minimize graft failure and associated TRM by infusing two partially matched UCB units were translated quickly from the myeloablative setting to RIC transplants. In a Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) phase II study, the 1-year NRM, relapse and survival rates in patients who received two UCB units were 24, 31 and 54%, respectively. 69 On the basis of this study and others, UCB is now an accepted source for RIC SCT.
The interest in using haploidentical donors in AML stems from their rapid availability and the potential for natural killer cellmediated GVL activity. 70 Using haploidentical donors, a regimen of Flu/CY/alemtuzumab resulted in low GvHD and 1-year survival of 31%, limited in large part by relapse and infections. 71 A different approach at Johns Hopkins University used Flu/CY/ TBI conditioning followed by post-transplant high-dose CY to eradicate alloreactive T cells. This approach resulted in consistent engraftment and low rates of chronic GvHD but disease relapse was still a hurdle with 2-year survival rates of 36%. 72 A BMT-CTN phase II study using haploidentical donors demonstrated 1-year NRM and survival rates of 7 and 62%. 69 Assuming that a well-matched donor is not available, the best choice between a haploidentical donor and double UCB in RIC SCT is not known. 73 In the BMT-CTN phase II studies, double UCB transplants resulted in higher NRM (24% at 1 year), whereas haploidentical transplants showed a high relapse rate (45% at 1 year). A comparable 1-year disease-free survival (DFS) was observed in both studies (46% for UCB and 48% for haploidentical transplants). The choice between these sources will be informed by the results of an ongoing prospective phase III study (NCT01597778). If survival results are comparable, additional factors such as cost and availability may determine the preferred graft source.
TOXICITY
Although RIC regimens consistently result in less regimen-related toxicity, the incidence of GvHD does not seem to be significantly lower in comparison with myeloablative transplants. Theoretically, lower conditioning intensity results in less tissue damage, cytokine production and inflammation; however, these advantages seem to be offset by the older age of recipients and donors (in sibling transplants), higher burden of comorbidities and the frequent use of PBSCs. 74 Notably, the presentation of GvHD after RIC SCT is often delayed. [75] [76] [77] [78] [79] [80] [81] [82] In our experience, more than half of acute GvHD cases present after day 100, a striking difference from myeloablative transplants.
Chronic GvHD is associated with protection against relapse after RIC transplants, similar to myeloablative transplants. 2, 18, 49, 83 However, it seems that after RIC, the benefit of reduced relapse rates in the context of chronic GvHD does not consistently translate into a survival benefit due to higher mortality in older patients with chronic GvHD. 26, 49 Interestingly, acute and chronic GvHD seem to increase the cost of RIC SCT to a greater extent than relapse. 84 Reduced-intensity and myeloablative regimens are associated with similar rates of infections and CMV reactivation, although early bacterial infections are less common after RIC, reflecting a shorter period of neutropenia. 81, 85, 86 There appears to be no advantage in reconstitution of cellular immunity. 86 Thymicdependent T-cell recovery is significantly compromised in elderly patients, especially in patients with chronic GvHD, in part explaining the high incidence of infections in RIC SCT recipients. 87 Therefore, the lower NRM using RIC regimens appears to be driven not by less GvHD and late opportunistic infections, but by lower rates of acute complications, such as mucositis, idiopathic pneumonitis, sinusoidal obstruction syndrome, hemorrhagic cystitis, nephrotoxicity and early bacterial infections. 18, 81, 86, [88] [89] [90] [91] [92] [93] [94] [95] Interestingly, the risk for secondary malignancies does not appear to be lower for RIC vs myeloablative transplants despite the lower doses of chemotherapy and radiation. 96 The differences in the toxicity profile impact the timing of complications. In one study of RIC vs myeloablative conditioning, NRM was lower for RIC in the first year after transplant, primarily in patients over age 40, but there were no significant differences after longer follow-up (13% vs 18% at 3 years). 97 Myeloablative transplants frequently result in early events of bacterial infections, hepatic and cardiopulmonary toxicity, whereas RIC SCT recipients frequently have an uncomplicated early course but later suffer equivalent rates of acute and chronic GvHD, and infections related to poor immune recovery. 91, 98, 99 The differences in toxicity profiles should direct patient selection and the type of monitoring needed; patients with suboptimal cardio-vascular, renal or hepatic function may still tolerate the early course of RIC transplants very well, but careful prophylaxis and management of infections and GvHD are critical in these patients to ensure a favorable long-term outcome. The differences in the timing of complications also underscore the need for long follow-up in both retrospective and prospective studies.
Long-term follow-up will also better define health-related quality of life, which is an important parameter in assessing transplant regimens. It seems that recipients of reduced-intensity and myeloablative conditioning recover their health-related quality of life similarly after transplant, 100 although one study reported faster recovery for RIC recipients. 101 A prospective study in patients with myeloid malignancies demonstrated similar recovery of functional status and health-related quality of life, although RIC recipients were less likely to report the recovery of cognitive function by 1 year compared with myeloablative recipients. 102 
PREDICTORS OF OUTCOME AND PERSONALIZED APPROACHES
The primary drawbacks of RIC SCT remain suboptimal disease control and treatment-related complications. To improve patient selection and monitoring strategies, it is important to identify characteristics that predict outcomes, both pre-and post-transplant.
Age is frequently discussed as a prognostic factor; age limits for SCT have been a moving target and studies typically define 'older' patients as 460 or 65. Within this range, age does not seem to predict NRM, relapse and survival according to two large registry studies. 22, 103 On the basis of these and other reports, 104-107 we do not use age alone as an eligibility criterion for SCT.
Underlying health problems and organ dysfunction have an immense impact on outcomes of RIC SCT. 104 NRM and survival can be predicted by the widely accepted hematopoietic cell transplantation comorbidity index and EBMT score, which were validated in several studies of RIC SCT in AML. [108] [109] [110] [111] [112] [113] It was recently shown that a composite score of age and hematopoietic cell transplantation comorbidity index further improves the prediction of NRM and survival, and may help identify patients who are more appropriate for RIC vs myeloablative transplantation. 114 Recently, the disease risk index was developed to help in prognostication and to allow comparisons between cohorts. This scoring system was predictive of survival in both myeloablative Reduced-intensity SCT for AML RIC (125) 60 ( Reduced-intensity SCT for AML R Reshef and DL Porter and RIC transplants. 115 The disease risk index for AML is calculated on the basis of the cytogenetic risk profile and disease status at the time of transplant, both previously shown to be independent predictors of relapse and survival. 17, 19, 29, 103, [116] [117] [118] [119] [120] An important predictor in early RIC studies was the absence of CR at the time of transplant, which predicted relapse and poor survival. 19, 29, 118, 119 A detailed discussion of emerging data on disease characteristics, such as cytogenetic and molecular abnormalities is beyond the scope of this review.
Graft composition impacts the outcome of RIC SCT. A high CD34+ cell dose improves engraftment and may improve survival after RIC. [121] [122] [123] In a study of 200 RIC SCT (Flu/Bu2) recipients, we found that a high CD8+ T-cell dose, which was restricted to young donors, was associated with improved relapse-free survival and OS. 124 A correlation between CD8+ T-cell dose and survival was previously observed after Flu/TBI2 125 but high CD8+ and CD34+ cell doses may also correlate with GvHD. 122, 126 Clearly, graft composition is a potentially modifiable determinant of outcome, though additional data are required.
Another potential strategy to improve outcomes through personalized approaches is to use donor chimerism levels as a surrogate for impending relapse and initiate interventions such as maintenance therapy or pre-emptive DLI. We found that low day-30 chimerism levels in RIC SCT recipients were a sensitive early predictor of relapse and poor survival. 127 Day-100 chimerism measurements were also predictive of survival in a series from Dana-Farber Cancer Institute. 128 In addition to chimerism, MRD detection could be used to predict relapse, though as yet there is no universal molecular or immunophenotypic marker for leukemic cells. This topic was recently reviewed elsewhere. 129, 130 Importantly, effective personalized approaches assume that MRD detection is coupled with effective interventions that prevent relapse and improve survival. Rapid tapering of immunosuppression and DLI are sometimes used at first signs of impending relapse but without prospective data to support this practice. Recently, 5-azacitidine was used to treat patients with AML who had donor CD34+ cell chimerism levels o 80%, potentially delaying the relapse in some patients. 131 Prospective randomized studies will be needed to show that outcomes can be improved using these risk-adapted interventions.
RELAPSE AFTER RIC SCT
Relapse is the major reason for mortality after RIC SCT. The incidence of AML relapse after RIC SCT was 32% in the EBMT registry, and OS following relapse was 14%. 132 Reported relapse rates have exceeded 40 or 50% with low-intensity regimens 27 or high-risk disease characteristics. 120, 133 The median interval to AML relapse after RIC SCT is short-3-7 months, 27, 119, 134, 135 and the median survival following relapse is 3-6 months. 135, 136 The EBMT identified three factors that predicted better survival after relapse-long interval from transplant to relapse, low percentage of BM blasts and absence of acute GvHD. In the presence of all three factors, the 2-year survival was 32%, but in their absence, it was only 4%. 132 Relapsed AML after RIC SCT is often treated with chemotherapy followed by DLI or a second transplant. Responses to DLI, after either RIC or myeloablative transplants, are observed in approximately one-third of patients, but do not always translate into long-term survival. 132, 134, 135, [137] [138] [139] [140] [141] The high relapse rate after RIC SCT has stimulated the development of prophylactic approaches that can be applied to high-risk patients. 5-Azacitidine has a favorable safety profile and good antileukemic activity in patients with low disease burden. 142 Interestingly, 5-azacitidine seems to reduce the rate of GvHD in both animal models and humans, possibly by supporting the expansion of Tregs. [143] [144] [145] It will be interesting to see whether improved outcomes with post-transplant 5-azacitidine will be driven by a reduction of relapse rates, a reduction in GvHD or both. Lenalidomide was also tested as post-transplant maintenance but an unacceptable rate of severe GvHD occurred at the dose that was tested.
146 FLT3 inhibitors for patients with FLT3-ITD mutations and other targeted therapies, as well as post-transplant vaccine approaches 147 are being explored in clinical trials, though definitive results are not yet available.
Several studies have investigated prophylactic DLI. The rationale is to use the low-toxicity conditioning regimen as a platform for early DLI that augments the GVL effect. Our group used an alemtuzumab-containing regimen, followed by an accelerated immunosuppression taper and prophylactic DLI, expanded and activated with CD3/CD28 costimulation. 148 The rate of GvHD after activated DLI was low and 28% of patients remain alive after a median follow-up of 58 months. Other groups have described similar approaches, showing a high rate of conversion from mixed to full donor chimerism. 149, 150 Early GvHD or relapse as well as unavailability of donors are the main obstacles of this approach.
REDUCED-INTENSITY VS MYELOABLATIVE CONDITIONING
Retrospective comparisons of RIC SCT to myeloablative transplants (summarized in Table 3 ) are difficult to interpret due to significant selection bias and short follow-up, which underestimates TRM from chronic GvHD and late infections. Patients allografted with RIC regimens usually have more high-risk features in terms of age, cytogenetic risk and comorbidities, and multivariate analyses are required to generate insightful conclusions. Nevertheless, retrospective studies so far suggest that the survival rates after RIC and myeloablative transplants are similar, despite differences in patient populations. 79 It appears that mortality is driven by different causes, with myeloablative transplants leading to higher NRM and RIC regimens resulting in more disease-related deaths. 75, 79, 151 The largest retrospective comparison of RIC and myeloablative conditioning included more than 5000 transplants reported to the CIBMTR. 79 Higher relapse rates were observed after RIC transplants and inferior survival was seen specifically after lower-intensity non-myeloablative conditioning (Flu/TBI2 or Flu/CY), a finding that was supported by a similar EBMT analysis. 82 Specifically, a subset of patients with favorable characteristics in the CIBMTR analysis (age 40-60, good performance status, AML in CR1) had worse DFS with non-myeloablative conditioning (P = 0.006). These results suggest that young and healthy patients with favorable risk AML do not benefit from reduced regimen intensity. Figure 1 . Choosing conditioning regimen intensity. The point of optimum is based on assessment of risks of regimen toxicity and disease relapse. These risks are affected by patient and disease characteristics.
Reduced-intensity SCT for AMLThese data highlight the importance of regimen intensity in patients with active disease or rapid progression, where the GVL response alone is insufficient to induce clinical benefit, whereas patients with significant comorbidities or older age might have better outcomes with RIC regimens.
To our knowledge, there is only one published prospective randomized trial of RIC vs myeloablative conditioning in patients with AML. 97 This study compared flu/TBI8 with a conventional myeloablative regimen (CY/TBI). There were no significant differences in the rates of NRM, relapse, DFS or OS. Drawing conclusions from this study is difficult due to several limitations; it enrolled patients up to age 61, the RIC regimen was more intense compared with commonly used RIC regimens and the trial closed early due to slow accrual.
A large prospective trial (BMT-CTN 0901) randomized patients with AML or MDS (age 18-65) to RIC or myeloablative conditioning. This trial aimed to enroll 356 patients with an end point of 18 months OS. The Data Safety and Monitoring Board closed the trial in April 2014 after enrolling 272 patients when preliminary review suggested a benefit for the myeloablative arm though no details are yet available. This early closure should not be considered a definitive answer and careful analysis of data will be required. In particular, we need to consider that patients were eligible only up to age 65 and were required to have good organ function and limited comorbidities (hematopoietic cell transplantation comorbidity index o4). Many patients with AML or MDS were ineligible for this study and selection bias may have affected patient enrollment. Ultimately, a detailed analysis of this trial with sufficient follow-up will be required before altering clinical practice.
The success of allo-SCT depends on minimizing the risks of regimen-related toxicity and disease relapse. These risks are affected by patient-and disease-specific parameters ( Figure 1 ) and insufficient data exist today to personalize regimen intensity. Prospective data are still immature and retrospective analyses have significant limitations. For now, in patients who appear to be clearly eligible for myeloablative conditioning on the basis of age, performance status and comorbid conditions, a full myeloablative regimen might be preferred. In all other patients, we can recommend matching the regimen intensity to each patient according to age, relapse risk, comorbidities and importantly, each patient's understanding and acceptance of the risks involved. SUMMARY RIC regimens have expanded the use of allogeneic SCT to elderly patients and patients with comorbidities who otherwise could not withstand the toxicity associated with myeloablative transplantation. RIC SCT has become routine if not standard in the care of AML but the high rate of relapse remains a challenge. The outcomes of RIC SCT can potentially be improved by better patient selection, effective maintenance regimens, better therapies for relapse and novel approaches to harness the GVL effect. An important question remains-how to personalize the regimen for each patient. We are not there yet, but are getting closer.
